GSK (GSK) said Monday that China's National Medical Products Administration has approved Nucala, or mepolizumab, as an add-on maintenance treatment of a certain chronic obstructive pulmonary disease in adult patients.
The approval was based on data from two phase III trials in which mepolizumab showed a "clinically meaningful and statistically significant" reduction in the annualized rate of exacerbations in patients, compared with placebo plus standard of care, the company said.
GSK shares were down 1% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments